Authors
Tyurin V.P., Davidyan S.Yu., Kiryukhina N.A., Rybakova D.V.
Pirogov National Medical and Surgical Center, Moscow
Abstract
Rheumatoid arthritis is a prevalent severe immunoinflammatory disease which defines its medical and socioeconomical significance. In 2020 olokizumab — biological product developed and produced in Russia — was registered by Ministry of Health of the Russian Federation for treatment of rheumatoid arthritis. Olokizumab is a humanized monoclonal antibody (IgG4-cappa type) specifically inhibiting interleukin-6 (IL-6). Product efficacy and safety were confirmed in recent international phase 3 clinical trials which included 2444 patients over 18 years old with moderate and severe rheumatoid arthritis (CREDO 1, CREDO 2, CREDO 3). This article describes the first experience with olokizumab use in the Department of rheumatology of Pirogov National Medical and Surgical center. The product was given to 17 patients with RA — 14 women and 3 men aged 20 to 75 years old, with typical clinical features^ they had polyarthritis with morning stiffness, joint tenderness and swelling on examination, increased ESR and CRB according to test results. The olokizumab therapy led to positive results both in naïve patients and in those previously treated with biologics. The rapid reduction of acute-phase reactants was accompanied by positive changes in articular syndrome. Longer observation is required for more detailed description of olokizumab efficacy and safety.
Keywords: rheumatoid arthritis, olokizumab, interleukin 6, biological disease-modifying antirheumatic products (BMARP), monoclonal antibodies (mAb).
References
1. Nasonov EL, Karateev DE, Balabanova RM. Revmatoidnyj artrit. V kn.: Revmatologiya. Nacional’noe rukovodstvo. E.L. Nasonov, V.A. Nasonovа, editors. Moskva: GEOTAR-Media; 2008. P.290-331. (In Russ.)
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388(10055): 2023-2038. doi: 10.1016/S0140-6736(16)30173-8.
3. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018; 32(2): 174-187. doi: 10.1016/j.berh.2018.10.005.
4. Folomeeva OM, Galushko EA, Erdes Gu SHF. Rasprostranennost’ revmaticheskih zabolevanij v populyaciyah vzroslogo naseleniya Rossii i SSHA. Nauchno-prakticheskaya revmatologiya. 2008; 4. (In Russ.)
5. Obshchaya zabolevaemost’ vzroslogo naseleniya Rossii v 2017 g. Statisticheskie materialy, chast’ IV, Moskva, 2018. [URL] (In Russ.)
6. Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014; 43(4): 479-88. doi: 10.1016/j.semarthrit.2013.08.004.
7. Associaciya Revmatologov Rossii. Klinicheskie rekomendacii po revmatoidnomu artritu 2021. (In Russ.)
8. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis in Kelley and Firestein’s Textbook of Rheumatology. 10th ed. Philadelphia, Pennsylvania: Elsevier; 2016: 1115-66.
9. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389(10086): 2328-2337. doi: 10.1016/S0140-6736(17)31472-1.
10. Catrina AI, Svensson CI, Malmström V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol. 2017; 13(2): 79-86. doi: 10.1038/nrrheum.2016.200.
11. Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya. 2017; 55(3): 277-94. (In Russ.) doi: 10.14412/1995- 4484-2017-277-294 6.
12. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita Nasonov EL, editor. Moscow: IMA-PRESS; 2013. (In Russ.)
13. Nasonov EL. Farmakoterapiya revmatoidnogo artrita: novaya strategiya, novye misheni. Nauchno-prakticheskaya revmatologiya. 2017; 55(4): 409-419. (In Russ.) doi: 10.14412/1995-4484-2017-409-419.
14. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69: 631-7. doi: 10.1136/ard.2009. 123919.
15. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75: 3-15. doi: 10.1136/annrheumdis-2015-20752.
16. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016; 75: 16-22.
17. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017; 389: 2338-48. doi: 10.1016/S0140- 6736(17)31491-5.
18. Smolen JS, Landewo RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis. 2020; 79: 685-99.
19. Ermakova YUA, Karateev DE, Luchihina EL, Demidova NV. Dinamika aktivnosti bolezni, funkcional’nogo statusa i rentgenologicheskih izmenenij pri rannem revmatoidnom artrite: rezul’taty 5-letnego nablyudeniya v ramkah rossijskoj programmy RADIKAL. Nauchno-prakticheskaya revmatologiya. 2015; 53(1): 17-23. (In Russ.)
20. Karateev DE, Luchihina EL, Demidova NV, et al. Pervoe rossijskoe strategicheskoe issledovanie farmakoterapii revmatoidnogo artrita (REMARKA): rezul’taty lecheniya 130 bol’nyh v techenie 12 mesyacev. Nauchno-prakticheskaya revmatologiya. 2014; 52(6): 607-14. (In Russ.)
21. Jeffrey A. Sparks. Rheumatoid Arthritis. Ann Intern Med. 2019; 170(1).
22. Moiseev SV, Novikov PI, CHebotareva NV, et al. Olokizumab v lechenii revmatoidnogo artrita. Klin farmakol ter. 2021; 30(2): 67-74. (In Russ.) doi: 10.32756/ 0869- 5490-2021-2-67-74.
23. Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference? BioDrugs. 2018; 32(6): 531-546. doi: 10.1007/s40259-018-0320-3.
24. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014; 6(3): 774-82. doi: 10.4161/mabs.28612.
25. Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014; 3(5): 388-395. doi: 10.1002/cpdd.121.16.
26. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014; 73(9): 1607-1615. doi: 10.1136/annrheumdis-2013-204760.
27. Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016; 26(1): 15-23. doi: 10.3109/14397595.2015.1074648.18.
28. Nasonov E, Stoilov R, Tyabut T on behalf of Saeed Fatenejad (United States of America), Krechikova D., Korneva E., Maslyansky A., et al. OP0021 olokizumab, monoclonal antibody against IL6, in patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of phase III CREDO-1 study. Annals of the Rheumatic Diseases. 2020; 79: 16-17. doi: 10.1136/annrheumdis-2020-eular.1688.
29. Nasonov EL, Lisicyna TA, Zonova EV, Kuz’kina SM. Vliyanie olokizumaba na iskhody, ocenivaemye pacientom s revmatoidnym artritom: rezul’taty dvojnogo slepogo randomizirovannogo placebo-kontroliruemogo mnogocentrovogo issledovaniya III fazy (CREDO 1). Nauchno-prakticheskaya revmatologiya. 2021; 59(1): 62-69. (In Russ.) doi: 10.47360/1995-4484-2021-62-69.
30. Feist E, Chohan S, Fatenejad S, Grishin S, Korneva E, Nasonov EL, Rowińska-Osuch A, Samsonov M. P131. Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study, Rheumatology. 2021; 60(1): 126, doi: 10.1093/rheumatology/keab247.126.
31. Feist E, Fatenejad S, Grishin S, Korneva E, Luggen M, Nasonov E, Samsonov M. P136. Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy. Rheumatology. 2021; 60(1): 132. doi: 10.1093/rheumatology/keab247.132.
32. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005; 23(5 S39): S93-9.
33. Kim KW, et al. Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis. Arthritis research & therapy. 2015; 17(1): 41.
34. Boettger MK, Leuchtweis J, Kümmel D, Gajda M, Bräuer R, Schaible HG. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010; 12(4): R140. doi: 10.1186/ar3079.
35. An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol 2019; 38(10): 2717-26.
36. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2016; 75(8): 1479-85. doi: 10.1136/annrheumdis-2015-208324.
37. Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. 2018; 4(2): e000773. doi: 10.1136/rmdopen-2018-000773.
